DORFSTRASSE 29, ZUG, V8
Reports on Week 16 Results of the VELA Phase 3 Hidradenitis Suppurativa Program with the Nanobody® Sonelokimab
Reports Second Quarter 2025 Financial Results and Provides a Business Update
Submission of Matters to a Vote of Security Holders
Results of Operations and Financial Condition
Reg. FD
Annual Report to Security Holders
Secures up to $500 Million in Non-Dilutive Financing and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
Earnings Release
Q2
Q1
FY 2023
Q3
FY 2023 amended
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence